Table 3.

Treatment-related adverse events.

Adverse event	No. of Patients (%)
	Erlotinib (n = 74)				Gefitinib (n =83)
	All grade	Grade 1–2	Grade 3	Grade 4	All grade	Grade 1–2	Grade 3	Grade 4
Rash	35 (47)	32 (43)	2 (3)	1 (1)	33 (40)	31 (37)	2 (2)	0
Diarrhea	12 (16)	12 (16)	0	0	16 (19)	15 (18)	1 (1)	0
Pruritus	9 (12)	9 (12)	0	0	15 (18)	15 (18)	0	0
Stomatitis	6 (8)	6 (8)	0	0	8 (10)	8 (10)	0	0
Increased ALT	15 (20)	14 (19)	1 (1)	0	22 (27)	16 (19)	5 (6)	1 (1)
Increased AST	11 (15)	11 (15)	0	0	21 (25)	17 (20)	3 (4)	1 (1)
Neutropenia	3 (4)	3 (4)	0	0	1 (1)	1 (1)	0	0
Increase bilirubin	3 (4)	3 (4)	0	0	8 (10)	8 (10)	0	0
Paronychia	2 (3)	2 (3)	0	0	3 (4)	3 (4)	0	0
Fatigue	1 (1)	1 (1)	0	0	2 (2)	2 (2)	0	0
Nausea/vomiting	1 (1)	1 (1)	0	0	4 (5)	4 (5)	0	0
Infection	1 (1)	1 (1)	0	0	1 (1)	1 (1)	0	0

ALT, alanine aminotransferase; AST, aspartate aminotransferase.